院長より
業績

トップページへ戻る


 トップページ院長より>業績〔1〕

業 績〔1〕

発表論文 (2016年2月現在)
1横山 宏樹: 包括的治療による合併症予防:糖尿病合併症.診断と治療のABC 124, 古屋大祐 企画.大阪, 最新医学社, p.287-297 , 2017.
2横山 宏樹: JDDM・横山研究からみた日本人糖尿病の管理・予後に関する特異性: 糖尿病の日本人特異性.月刊糖尿病vol. 9, No.6, p. 72-83 , 2017.
3Yokoyama H, Oishi M, Takamura H, Yamasaki K, Shirabe S, Uchida D, Sugimoto H, Kurihara Y, Araki S, Maegawa H: Large-scale survey of rates of achieving targets for blood glucose, blood pressure, and lipids and prevalence of complications in type 2 diabetes(JDDM40) : BMJ Open Diabetes Research and Care 2016;4:e000294. doi:10.1136/bmjdrc-2016-000294
4Otani T, Yokoyama H, Ohashi Y, Uchigata Y: Improved incidence of end-stage renal disease of type 1 diabetes in Japan, from a hospital-based survey : BMJ Open Diabetes Research and Care 2016;4:e000177. doi:10.1136/bmjdrc-2015-000177
5Mita T, Katakami N, Shiraiwa T, Yoshii H, Onuma T, Kuribayashi N, Osonoi T, Kaneto H, Kosugi K, Umayahara Y, Yamamoto T, Matsumoto K, Yokoyama H, Tsugawa M, Gosho M, Shimomura I, Watada H: Collaborators on the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE) Trial. Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial. Diabetes Care 39(3):455-64, 2016.
6Takahara M, Shiraiwa T, Abe K, Ishimaru Y,Iwamoto M,Shimizu M,Tomonaga O,Yokoyama H: Variations in the associations of taste-related words with foods in diabetic patients in Japan according to gender, age, and geographical region: a multicenter study conducted in seven regions of Japan :Diabetol Int 7:314-320, 2016
7横山 宏樹, 前川 聡: JDDM: 日本人糖尿病の大規模臨床・疫学研究.Diabetes Frontier vol.26 No.6, p. 713-721 , 2015.
8横山 宏樹, 水谷 有加利, 堀口 真恵: 血圧管理とそのコツ: 糖尿病腎症の診断と治療 Up To Date.月刊糖尿病vol. 7, No.12, p. 34-40 , 2015.
9Yokoyama H,Ogawa M,Honjo J,Okizaki S,Yamada D,Shudo R,Shimizu H,Sone H,Haneda M: Risk factors associated with abnormal cognition in Japanese outpatients with diabetes, hypertension or dyslipidemia: Diabetol Int 6:268-274,2015.
10Yokoyama H, Araki S, Watanabe S, Honjo J,Okizaki S,Yamada D,Shudo R,Shimizu H,Sone H,Haneda M: Prevalence of resistant hypertension and associated factors in Japanese subjects with type 2 diabetes : Diabetes Res Clin Pract 110:18-25,2015.
11Yokoyama H, Araki S,Kawai K,Hirao K,Oishi M, Sugimoto K,Sone H,Maegawa H, Kashiwagi A ,and on behalf of Japan Diabetes Clinical Data Management Study Group : Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease(JDDM36): Diabetes Res Clin Pract 109:485-92,2015.
12Otani T, Yokoyama H, Uchigata Y: Changes in the prognosis of Japanese patients who developed type 1 diabetes before the age of 30 years: Diabetes Res Clin Pract 109:434-439,2015.
13横山 宏樹: 糖尿病性腎症進展抑制における血糖管理の意義(保存期):糖尿病と腎疾患2015, 腎と透析2015, vol.78増刊号, 腎と透析編集委員会編.東京, 東京医学社, p. 424-428, 2015
14横山 宏樹: 各施設でのCKDチーム医療の実践:CKDチーム医療のテキスト. 海津嘉蔵 編著. 東京, 日本医事新報社, p. 74-83, 2015
15Wada T, Haneda M, Furuichi K, Babazono T, Yokoyama H, Iseki K, Araki S, Ninomiya T, Hara S, Suzuki Y, Iwano M, Kusano E, Moriya T, Satoh H, Nakamura H, Shimizu M, Toyama T, Hara A, Makino H: Research Group of Diabetic Nephropathy, Ministry of Health, Labour, and Welfare of Japan. Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes. Clin Exp Nephrol 18: 613-20, 2014.
16Yokoyama H,Sone H,Honjo J,Okizaki S,Yamada D,Shudo R,Shimizu H,Moriya T and Haneda M: Relationship between a Low Ankle Brachial Index and All-Cause Death and Cardiovascular Events in Subjects with and without Diabetes. J Atheroscler Thromb 21(6):574-581, 2014
17Toyoda M,Yokoyama H,Abe K,Nakamura S,Suzuki D: Predictors of response to liraglutide in Japanese type 2 diabetes: Diabetes Res Clin Pract 106:451-457,2014
18Mikada A, Narita T, Yokoyama H, Yamashita R, Horikawa Y, Tsukiyama K, Yamada Y: Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. ‘‘The MASTER randomized, controlled trial’’, diabetes research and clinical practice 106:538-547, 2014
19Yokoyama H、Hirao K, Yamaguchi K, Oishi M, Gendai L, Yagi N, Takamura H, Kashiwagi A ,and on behalf of the Japan Diabetes Clinical Data Management Study Group: Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33), Japanese Clinical Medicine:5, 33-41, 2014
20横山 宏樹: 厳格血糖・血圧コントロールによる顕性腎症のremission. 糖尿病学2014. 門脇 孝 編. 東京, 診断と治療社, p. 94-102, 2014
21横山 宏樹, Peter Rossing, 井関 邦敏, 二宮 利治, (座談会)糖尿病患者における治療戦略-心腎関連の観点から‐:糖尿病診療マスター.vol.12 No.8,S1-S7,2014
22Yokoyama H, Araki S, Honjo J, Okizaki S, Yamada D, Shudo R, Shimizu H, Sone H, Moriya T, Haneda M: Association between remission of macroalbuminuria and preservation of renal function in patients with type 2 diabetes with overt proteinuria. Diabetes Care 36:3227?3233, 2013.
23横山 宏樹: Steno-2studyからJDDMstudyへ:最新臨床糖尿病学(上)糖尿病学の最新動向,日本臨床,70巻,増刊号3,p295-300,2012 
24Narita T, Yokoyama H, Yamashita R, Sato T, Hosoba M, Morii T, Fujita H, Tsukiyama K, Yamada Y: Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. Diabetes Obes Metab.:14(3):283-7, 2012
25横山 宏樹: 腎症の診断と評価(尿検査). 糖尿病腎症のすべて. 荒木 栄一 編集主幹. 東京, 中山書店, p. 84-8, 2012
26横山 宏樹: 疫学調査、臨床科学に基づく現状と今後:糖尿病性腎症の現況と今後の展望. Diabetes Frontier 23:520-7, 2012
27Yokoyama H, Araki S, Haneda M, Matsushima M, Kawai K, Hirao K, Oishi M, Sugimoto K, Sone H, Maegawa H, Kashiwagi A:Chronic kidney disease categories and renal-cardiovascular outcomes in type 2 diabetes without prevalent cardiovascular disease: a prospective cohort study (JDDM25). Diabetologia 55: 1911-1918, 2012
28横山 宏樹: 糖尿病性腎症の治療と予後、JDDMを含めた最新の知見から. Nephrology Frontier 11:54-9, 2012
29Oishi M, Yokoyama H, Abe N, Iwasaki K, Okuguchi F, Kawai K, Sugimoto H, Takamura H, Takeda H, Doi K, Hirao K, Ikeda S: Time and Costs of Insulin Treatment in the Care of Newly Registered Type 2 Diabetes Patients in Diabetes Clinics Across Japan (JDDM 22). Japanese Clinical Medicine :2:9, 2011
30Yokoyama H, Kanno S, Takahashi S, Yamada D, Honjo J, Saito K, Sone H, Haneda M: Risks for glomerular filtration rate decline in association with progression of albuminuria in type 2 diabetes. Nephrol Dial Transplant 26:2924-30, 2011
31Yokoyama H, Matsushima M, Kawai K, Hirao K, Oishi M, Sugimoto H, Takeda H, Minami M, Kobayashi M, Sone H: Low incidence of cardiovascular events in Japanese patients with Type 2 diabetes in primary care settings: a prospective cohort study (JDDM 20). Diabet Med 28:1221-8, 2011
32Yokoyama H, Sone H, Saito K, Yamada D, Honjo J, Haneda M: Flow-mediated dilation is associated with microalbuminuria independent of cardiovascular risk factors in type 2 diabetes - interrelations with arterial thickness and stiffness. J Atheroscler Thromb 18:744-52, 2011
33Yokoyama H, Sone H, Yamada D, Honjo J, Haneda M: Contribution of glimepiride to basal-prandial insulin therapy in patients with type 2 diabetes. Diabetes Res Clin Pract 91:148-53, 2011
34横山 宏樹: ビグアナイド、血圧・血糖・脂質管理のKey Drugs. 薬局 62:2475-7, 2011
35横山 宏樹: チアゾリジン誘導体、血圧・血糖・脂質管理のKey Drugs. 薬局 62:2480-2, 2011
36横山 宏樹: 心血管疾患の罹患や発症へ家族歴が及ぼす影響 : 非糖尿病者および糖尿病者の知見から. 糖尿病 53:325-30, 2010
37横山 宏樹: 日本でのインスリン治療研究、Yokoyama Studyとは. 糖尿病レクチャー、最新外来インスリン療法. 清野 弘明 編集. 東京, 総合医学社, p. 369-72, 2010
38横山 宏樹: 配合剤を構成する医薬品のプロフィル チアゾリジン、配合剤の実力を探る. 薬局 61:3486-7, 2010
39横山 宏樹: 配合剤を構成する医薬品のプロフィル メトホルミン、配合剤の実力を探る. 薬局 61:3488-9, 2010
40横山 宏樹: 配合するには理由がある! チアゾリジン+メトホルミン、配合剤の実力を探る. 薬局 61:3518-9, 2010
41Yokoyama H, Inoue T, Node K: Effect of insulin-unstimulated diabetic therapy with miglitol on serum cystatin C level and its clinical significance. Diabetes Res Clin Pract 83:77-82, 2009
42Yokoyama H, Kanno S, Takahashi S, Yamada D, Itoh H, Saito K, Sone H, Haneda M: Determinants of decline in glomerular filtration rate in nonproteinuric subjects with or without diabetes and hypertension. Clin J Am Soc Nephrol 4:1432-40, 2009
43Yokoyama H, Sone H, Oishi M, Kawai K, Fukumoto Y, Kobayashi M: Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant 24:1212-9, 2009
44横山 宏樹: 臨床で役立つチアゾリジンの処方設計と副作用管理、脂肪肝に効果があって肝障害患者に禁忌である理由. 薬局 60:276-7, 2009
45横山 宏樹: チアゾリジンが臨床で期待される作用とそのエビデンス、脂肪肝に対する作用. 薬局 60:235-7, 2009
46横山 宏樹: チアゾリジンが臨床で期待される作用とそのエビデンス、血糖改善作用. 薬局 60:208-9, 2009
47横山 宏樹: インスリン治療-科学的根拠とその実践-多彩化するインスリン製剤を使いこなすための科学的背景は、さまざまな経口薬とインスリンの併用療法に真のメリットはあるのか. Diabetes Frontier 20:188-93, 2009
48横山 宏樹: 実際のクリニックにおける導入アウトライン、自由が丘横山内科クリニックでの導入アウトライン. これでわかる外来インスリン導入と管理、実例から学ぼう!. 清野 弘明, 朝倉 俊成 編集. 東京, 南江堂, p. 107-10, 2009
49横山 宏樹: こんな患者さんにはこうやって導入-困難例への対処法、自由が丘横山内科クリニックでの困難患者さん. これでわかる外来インスリン導入と管理、実例から学ぼう!. 清野 弘明, 朝倉 俊成 編集. 東京, 南江堂, p. 133-6, 2009
50横山 宏樹, 山下 りさ, 石村 郁恵, 松本 由紀子, 菅野 咲子: 内科側から考える妊娠糖尿病の産前、産後の管理、ワークショップ:わが国における妊娠糖尿病を考える. 糖尿病と妊娠 9:58-9, 2009


>業績〔2〕

〒080-0016 北海道帯広市西6条南6丁目4-3  TEL 0155-20-5011 FAX 0155-20-5015
E-mail info@yokoyamanaika.com
Copyright (C) 2008 Jiyugaoka Medical Clinic, Internal Medicine All Rights Reserved.